We write to bring to the attention a development concerning one of the studies cited in our umbrella review published in Diabetic Medicine in 2022.1 A study that was included in the review has recently been retracted.2 This retracted study informed our conclusion regarding the potential benefit of intensive blood pressure monitoring versus standard of care for diabetic retinopathy outcomes. It is therefore essential to acknowledge this development in the interests of scientific integrity and transparency. While the retraction of the study was not due to any error on our part, it means we can no longer maintain the same level of confidence in one of our findings with regard to intensive blood pressure monitoring for diabetic retinopathy. This situation highlights the evolving nature of the scientific literature and the importance of ongoing vigilance in evidence synthesis and underscores the value of umbrella reviews and living systematic reviews in maintaining current and reliable evidence bases, as they allow for such updates when new information emerges. We would encourage readers to interpret our original conclusions regarding intensive blood pressure monitoring with appropriate caution until further high-quality evidence becomes available. The remainder of our review's findings, which were based on other independent studies, remain valid. I thank the editorial team for their guidance on the appropriate mechanism to communicate this important update to the scientific community. Open access publishing facilitated by The University of Queensland, as part of the Wiley - The University of Queensland agreement via the Council of Australasian University Librarians
Trott et al. (Mon,) studied this question.